Trial Profile
A Phase I/II, Open-Label, Multiple-Dose, Dose Escalation and Expansion Study to Investigate the Safety and Pharmacokinetics of the BTK Inhibitor BGB-3111 in Subjects With B-Cell Lymphoid Malignancies
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 31 Jul 2023
Price :
$35
*
At a glance
- Drugs Zanubrutinib (Primary)
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions; First in man; Registrational; Therapeutic Use
- Sponsors BeiGene
- 15 Jun 2023 Results of pooled analysis from NCT03846427 and NCT02343120 assessing unanchored MAIC to estimate the comparative efficacy of ZANU versus IBRU in R/RMZL presented at the 28th Congress of the European Haematology Association
- 15 Jun 2023 Results of pooled analysis from (BGB-3111-AU-003, BGB-3111-215, BGB-3111-216, BGB-3111-1002,BGB-3111-GA-101) assessing comparative summary of safety and efficacy data between the QD and BID regimens in patients with various B-cell malignancies presented at the 28th Congress of the European Haematology Association
- 06 Jun 2023 Results assessing matching-adjusted indirect comparison to estimate efficacy of zanubrutinib versus ibrutinib in relapsed/refractory marginal zone lymphoma, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.